RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.

A recent study published in Genomic Psychiatry has unveiled a promising new therapy that may help improve memory and reduce ...

Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

Using a gene signature technique to tailor chemotherapy for patients with early triple negative breast cancer shows promise as a way to improve disease-free survival, finds a clinical trial published ...

Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss ...

Zodasiran, an RNA interference (RNAi) therapy targeting angiopoietin-like 3 (ANGPTL3), resulted in a dose-dependent reduction ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...

结论：这项研究揭示了在肿瘤中广泛积累的异常 miRNA 异构体，并开发了一种通过编辑和修复有缺陷的 miRNA 来实现的植物 RDR1 介导的抗肿瘤策略。这些发现为癌症治疗提供了新的视角，即通过利用植物免疫蛋白来修复肿瘤中的 miRNA 缺陷，从而抑制肿瘤生长。

Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the ...